CD38 and Miyoshi myopathy: These outstanding results add to the growing body of literature demonstrating the profound efficacy of CD38 antibodies, proteasome inhibitors (PI), immunomodulators (IMiD), and steroids for treating newly diagnosed MM, with a majority of patients with newly diagnosed MM achieving durable disease control regardless of how these three drug classes are utilized.